![]() ![]() All abstracts for the ESGCT Annual Congress will be available on ESGCT’s website here. Presenting Author: Aaron Prodeus, Ph.D., principal scientist, Cell TherapyĪdditional data collected will be included in final meeting presentations. Title: Lipid Nanoparticles (LNPs) as a Superior CRISPR/Cas9 Delivery Modality for Highly Efficient Multiplex Gene Editing of T Cells for Adoptive Cell Therapyĭate/Time: Tuesday, October 19, 2021, 8:00 a.m. Location: Session 7b: Liver and metabolic diseases II Title: Advances in CRISPR/Cas9 Therapeutic Genome Editing for In Vivo and Ex Vivo Applicationsĭate/Time: Friday, October 22, 2021, 11:30 a.m. Presenting Author: Sean Burns, M.D., vice president of Intellia’s Disease Biology and Pharmacology group ![]() Title: Consecutive Genome Editing in Non-Human Primate Achieves Durable Production of Human Alpha-1 Antitrypsin at Physiologic Levels and Reduction of the Homologous Native Proteinĭate/Time: Wednesday, October 20, 2021, 10:15 a.m. Presenting Author: Yong Zhang, Ph.D., associate director, Cell Therapy Location: Session 2c: Immunotherapy for cancer & CAR T cells Title: A Novel Strategy for Off-the-shelf T Cell Therapies Evading Host T Cell and NK Cell Rejectionĭate/Time: Wednesday, October 20, 2021, 10:45 a.m. We look forward to sharing these data with the scientific community as we continue to advance our mission of delivering breakthrough genome editing treatments for people with severe diseases.” For AATD, a genetic disease that can cause lung dysfunction and/or liver disease and which currently has no cure, our modular delivery platform provides us the optionality for patient-tailored treatments relevant to the disease manifestation. “Additionally, we will be presenting non-human primate data from our in vivo platform where we have demonstrated our ability to both insert a functional gene and inactivate a gene to treat AATD. “We are excited to share for the first time important preclinical data and new developments highlighting both our allogeneic T cell therapy platform as well as the utilization of lipid nanoparticle-based delivery of the CRISPR/Cas9 gene editing components to more efficiently engineer T cells for therapeutic use,” said Intellia Chief Scientific Officer Laura Sepp-Lorenzino, Ph.D. ![]() (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of new data at the 29 th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) meeting, taking place virtually from October 19-21, 2021. 12, 2021 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |